• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Agilent Technologies Inc.

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email
    SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _ )*

                

    AGILENT TECHNOLOGIES, INC.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    00846U101


    (CUSIP Number)

    September 30, 2024


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 00846U101

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Massachusetts Financial Services Company ("MFS")
    04-2747644
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    Not Applicable
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 15,128,505
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 15,589,874
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    15,589,874 shares of Common Stock consisting of shares beneficially owned by MFS and/or certain other non-reporting entities
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    Not Applicable
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.4%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    AGILENT TECHNOLOGIES, INC.
    (b) Address of Issuer's Principal Executive Offices
    5301 Stevens Creek Blvd, Santa Clara, CA 95051
    Item 2.
    (a) Name of Person Filing
    Massachusetts Financial Services Company
    (b) Address of Principal Business Office or, if None, Residence
    111 Huntington Avenue, Boston, MA 02199
    (c) Citizenship
    Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    00846U101
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    15,589,874 shares of Common Stock consisting of shares beneficially owned by MFS and/or certain other non-reporting entities
    (b) Percent of Class:
    5.4%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 15,128,505
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 15,589,874
    (iv) shared power to dispose or to direct the disposition of 0
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.
    Not Applicable
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Massachusetts Financial Services Company
    By: /s/ Lisa Neaves
    Date: November 12, 2024
    Name: Lisa Neaves
    Title: Compliance Officer

    Get the next $A alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    8/28/2024$157.00Overweight
    Wells Fargo
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/3/2024$135.00Hold
    Jefferies
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    12/13/2023$140.00Outperform
    Wolfe Research
    12/12/2023$130.00 → $133.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Smackover Lithium Submits Royalty Application to Arkansas Oil and Gas Commission for South West Arkansas Project

      LEWISVILLE, Ark., May 06, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, announced that SWA Lithium LLC has submitted an application to the Arkansas Oil and Gas Commission ("AOGC") to establish a fair and equitable lithium royalty for the Reynolds Unit for Phase I of its South West Arkansas ("SWA") Project in Lafayette and Columbia Counties, Arkansas. The hearing is scheduled for Wednesday, May 28th, 2025, at 9:00 am CDT and is to be held at the Donald W. Reynolds Community Center Grand Hall at South Arkansas University (100 East University) in Magnolia, Arkansas. The a

      5/6/25 8:30:43 AM ET
      $A
      $SLI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Major Chemicals
    • Agilent Unveils Transformative Seahorse XF Flex Analyzer: Revolutionizing 3D Tissue and Organoid Research

      Agilent Technologies Inc. (NYSE:A) today announced release of the new Seahorse XF Flex Analyzer, a high-performance, 24-well system designed to expand real-time metabolic analysis into optimized 3D tissue and organoid workflows, along with dedicated consumables and kit. Metabolism is vital for cellular functions, driving energy production and essential processes such as biosynthesis, adaptation, redox balance, mitochondrial function, and cell fate decisions. Disruptions in metabolism can lead to many diseases, making its analysis crucial for uncovering disease mechanisms and developing novel therapies. Interest in analyzing cellular metabolism in complex 3D biological models, such as tissu

      5/1/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Smackover Lithium's South West Arkansas Project Receives Unanimous Vote of Approval to Establish the Phase I Brine Production Unit from the Arkansas Oil and Gas Commission

      LEWISVILLE, Ark., April 24, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is pleased to announce that the brine production unit, now formally named the Reynolds Unit, for Phase I of its South West Arkansas ("SWA") Project has been unanimously approved by the Arkansas Oil and Gas Commission ("AOGC") with no objections or opposition in a hearing that was open to all stakeholders from the community. "We thank the AOGC for their due diligence in reviewing our application and for their swift approval," said Standard Lithium's President and COO, Dr. Andy Robinson, who prov

      4/24/25 8:30:04 AM ET
      $A
      $SLI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Major Chemicals

    $A
    Leadership Updates

    Live Leadership Updates

    See more
    • Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

      Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

      4/24/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent to Acquire North American CDMO BIOVECTRA

      Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

      7/22/24 9:01:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

      Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

      6/26/24 8:00:00 AM ET
      $A
      $ANIK
      $AVNT
      $MASI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical/Dental Instruments
      Health Care

    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

      SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/12/24 1:27:37 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Agilent Technologies Inc.

      SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/12/24 11:54:03 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Agilent Technologies Inc.

      SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/4/24 10:57:57 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    SEC Filings

    See more
    • SEC Form 8-K filed by Agilent Technologies Inc.

      8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

      5/2/25 4:01:23 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

      4/2/25 4:58:34 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

      3/17/25 4:30:08 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agilent upgraded by Barclays with a new price target

      Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously

      2/10/25 6:55:03 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wells Fargo initiated coverage on Agilent with a new price target

      Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00

      8/28/24 7:20:29 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent upgraded by Citigroup with a new price target

      Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously

      7/10/24 7:22:08 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Gonsalves Rodney (Amendment)

      4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      10/20/23 1:07:25 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      9/29/23 4:03:46 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Senior Vice President May Simon covered exercise/tax liability with 368 shares, decreasing direct ownership by 5% to 7,491 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      5/9/25 5:03:01 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sr Vice President Ancher-Jensen Henrik covered exercise/tax liability with 132 shares, decreasing direct ownership by 0.15% to 88,181 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      5/6/25 1:36:09 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Podolsky Daniel K sold $211,844 worth of shares (1,819 units at $116.46), decreasing direct ownership by 5% to 35,737 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      4/2/25 5:07:36 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    Financials

    Live finance-specific insights

    See more
    • Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

      Agilent Technologies Inc. (NYSE:A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Ag

      4/16/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Reports First-Quarter Fiscal Year 2025 Financial Results

      Delivers solid Q1 results, confirms core growth and EPS for 2025 fiscal year First-quarter fiscal year 2025 Revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% on a core(1) basis compared with the first quarter of 2024. GAAP net income of $318 million; earnings per share (EPS) of $1.11, down 6% from the first quarter of 2024. Non-GAAP(2) net income of $377 million; EPS of $1.31, up 2% from the first quarter of 2024. Outlook for full 2025 fiscal year and Q2 Full-year revenue outlook is now in the range of $6.68 billion to $6.76 billion, representing a range of up 2.6% to 3.8% reported and 2.5% to 3.5% core(1).

      2/26/25 4:04:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Announces Cash Dividend of 24.8 Cents per Share

      Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on April 23, 2025, to all shareholders of record as of the close of business on April 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted a

      2/19/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials